Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2010 Feb;125(2):295–302. doi: 10.1016/j.jaci.2009.12.014

Table 2.

Factors Affecting the Likelihood that a Pharmacogenomic Association will Alter Practice

1. Frequency of the variant(s) of interest in the population
 -Increased frequency increases the likelihood that testing for the association will make economic sense and is worthy of consideration.
2. Strength of the association between the polymorphism and the drug effect
 -The stronger the predictive value of the association the greater the potential utility of the test.
3. Impact of the making the “right” vs. “wrong” choice
 -If the consequences of the choice are associated with high morbidity then even if the frequency of the polymorphism is low, it may still make sense to test especially if the strength of the association is high.